US biotech company Moderna on Thursday posted a narrower net loss for the second quarter compared to last year. However, the loss was still greater than market expectations, largely due to weaker-than-anticipated revenues. In pre-market activity on the Nasdaq, Moderna shares were losing around 12% to trade at $104.94. For the second quarter, the net loss was $1.28 billion, compared to the prior year’s loss of $1.38 billion. Net loss per share was $3.33 for the second quarter, compared to $3.62 net loss a year ago. Total revenue for the second quarter was $241 million, down from $344 million in…